Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
A Phase III, Randomized, Observer-Blind, Controlled, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
Sponsor: Seqirus
This PHASE3 trial investigates Influenza and is currently completed. Seqirus leads this study, which shows 12 recorded versions since 2016 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jul 2020 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Feb 2019 — Jul 2020 [monthly]
Completed PHASE3
-
Sep 2018 — Feb 2019 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jul 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE3
-
Oct 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Oct 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Sep 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Seqirus
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alor Star, Malaysia , Ankara, Turkey (Türkiye) , Antalya, Turkey (Türkiye) , Arad, Romania , Armenia, Colombia , Balvi, Latvia , Bangkok, Thailand , Barranquilla, Colombia , Batu Caves, Malaysia , Bogotá, Colombia and 60 more locations